Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys. by Krentel, Alison et al.
Krentel, A; Damayanti, R; Titaley, CR; Suharno, N; Bradley, M; Ly-
nam, T (2016) Improving Coverage and Compliance in Mass Drug
Administration for the Elimination of LF in Two ’Endgame’ Districts
in Indonesia Using Micronarrative Surveys. PLoS neglected tropical
diseases, 10 (11). e0005027. ISSN 1935-2727 DOI: 10.1371/jour-
nal.pntd.0005027
Downloaded from: http://researchonline.lshtm.ac.uk/3079627/
DOI: 10.1371/journal.pntd.0005027
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE
Improving Coverage and Compliance in
Mass Drug Administration for the
Elimination of LF in Two ‘Endgame’ Districts
in Indonesia Using Micronarrative Surveys
Alison Krentel1*, Rita Damayanti2, Christiana Rialine Titaley2, Nugroho Suharno2,
Mark Bradley3, Timothy Lynam4
1 Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
London, United Kingdom, 2 Center for Health Research, Faculty of Public Health, Universitas Indonesia,
Jakarta, Indonesia, 3 Global Health Programs, GlaxoSmithKline, London, United Kingdom, 4 Reflecting
Society Pty Ltd, Townsville, Australia
* alison.krentel@lshtm.ac.uk
Abstract
Background
As the Global Programme to Eliminate Lymphatic Filariasis (LF) approaches its 2020 goal,
an increasing number of districts will enter the endgame phase where drug coverage rates
from mass drug administration (MDA) are used to assess whether MDA can be stopped.
As reported, the gap between reported and actual drug coverage in some contexts has
overestimated the true rates, thus causing premature administration of transmission
assessment surveys (TAS) that detect ongoing LF transmission. In these cases, districts
must continue with additional rounds of MDA. Two districts in Indonesia (Agam District,
Depok City) fit this criteria—one had not met the pre-TAS criteria and the other, had not
passed the TAS criteria. In both cases, the district health teams needed insight into their
drug delivery programs in order to improve drug coverage in the subsequent MDA rounds.
Methodology/Principal Findings
To inform the subsequent MDA round, a micronarrative survey tool was developed to cap-
ture community members’ experience with MDA and the social realm where drug delivery
and compliance occur. A baseline survey was implemented after the 2013 MDA in endemic
communities in both districts using the EPI sampling criteria (n = 806). Compliance in the
last MDA was associated with perceived importance of the LF drugs for health (p<0.001);
perceived safety of the LF drugs (p<0.001) and knowing someone in the household has
complied (p<0.001). Results indicated that specialized messages were needed to reach
women and younger men. Both districts used these recommendations to implement
changes to their MDA without additional financial support. An endline survey was per-
formed after the 2014 MDA using the same sampling criteria (n = 811). Reported
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005027 November 3, 2016 1 / 22
a11111
OPENACCESS
Citation: Krentel A, Damayanti R, Titaley CR,
Suharno N, Bradley M, Lynam T (2016) Improving
Coverage and Compliance in Mass Drug
Administration for the Elimination of LF in Two
‘Endgame’ Districts in Indonesia Using
Micronarrative Surveys. PLoS Negl Trop Dis 10
(11): e0005027. doi:10.1371/journal.pntd.0005027
Editor: Wilma A. Stolk, Erasmus MC,
NETHERLANDS
Received: February 23, 2016
Accepted: September 9, 2016
Published: November 3, 2016
Copyright: © 2016 Krentel et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper, its Supporting Information files
and through the Open Science Framework under
DOI 10.17605/OSF.IO/7D5HR.
Funding: Funding for this research was provided
by GSK. GSK had no role in the study design, data
collection, analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: MB is a contributing author
on this manuscript and is an employee at GSK. TL
compliance in the last MDA improved in both districts from 57% to 77% (p<0.05). Those
who reported having ever taken the LF drug rose from 79% to 90% (p<0.001) in both sites.
Conclusions/Significance
Micronarrative surveys were shown to be a valid and effective tool to detect operational
issues within MDA programs. District health staff felt ownership of the results, implementing
feasible changes to their programs that resulted in significant improvements to coverage
and compliance in the subsequent MDA. This kind of implementation research using a
micronarrative survey tool could benefit underperforming MDA programs as well as other
disease control programs where a deeper understanding is needed to improve healthcare
delivery.
Author Summary
This research describes the process used to assist two districts endemic for lymphatic filari-
asis (LF) in Indonesia to better understand the reasons why their LF elimination programs
have had suboptimal results. A novel survey design was used to collect stories about peo-
ple’s direct experienceswith mass drug administration (MDA) for LF. These question-
naires also explored the reasons community members took or did not take the LF drugs.
Following MDA in 2013, two baseline surveys in endemic communities provided insight
into the districtMDA programs. Together with district health officials, feasible recom-
mendations were provided before the next MDA round in 2014. Uptake of these recom-
mendations by the districts was high, although no additional funding was made available
for programmatic changes. As a result, both districts reported significant improvements in
their MDA coverage and compliance rates after the endline surveyswere completed in
2015. This demonstrated the utility of the survey tool and process to impact change and
improvement in MDA programs.
Introduction
More than fifteen years ago, the Global Programme to Eliminate Lympatic Filariasis (GPELF)
was launched with the goal to interrupt transmission of the disease in endemic countries by
2020 [1]. Considerable progress in reducing transmission and burden of disease has beenmade
sinceWorld Health Assembly Resolution 50.29 prioritized the elimination of lymphatic filaria-
sis (LF) in 1997. Since the start of LF elimination, there has been an estimated 46% reduction
of the population living at risk for LF infection [2], over 96 million LF cases cured or prevented
[3, 4] as well as billions of dollars of direct economic benefits in endemic countries [5].
At the end of 2014, of the 73 countries known to be endemic for lymphatic filariasis (LF), 55
required ongoing mass drug administration (MDA) as the recommended preventive chemo-
therapy (PC) to eliminate LF [4]. Eleven endemic countries still need to beginMDA and 23
countries have less than 100% geographical coverage [4]. As 2020 approaches, there is an
increased urgency to scale up activities in these remaining countries. On the other side of the
spectrum, implementation units (IUs) that have completed at least five effectiveMDA rounds
qualify for Transmission Assessment Surveys (TAS) to evaluate the level of LF transmission in
the population and to determine if MDA can be stopped [6]. For those IUs who do not qualify
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for TAS due to persistent low MDA coverage or whomust repeat MDA rounds because the
critical threshold has been surpassed, a new set of implementation challenges appears. The
peer-reviewed literature has not sufficiently addressed these issues. As such, there is a gap in
our understanding as to how to guide and assist those IUs when additional MDA rounds must
be implemented past the expected 4–6 rounds suggested by the programme [7].
This research aims to respond to that gap in understanding through the development of a
tool and process to assist ‘endgame’ IUs in understanding why drug coverage may be persis-
tently low, what specific actions may be undertaken to improve delivery and uptake and how
those responsible for deliveringMDA may be better supported. Although the issue of low cov-
erage is not a new one, it has become increasingly recognized as the 2020 deadline approaches
for LF elimination. Recent reviews on factors associated with coverage and compliance with
antihelmintic treatment highlight some of the pertinent issues that need addressing [8–10].
These reviews report similar findings across global and Indian-specific contexts. Notable issues
that negatively impact compliance with treatment include fear of side effects, not feeling LF
drugs are needed, lack of trust, distributor not coming and taking too many tablets. These
reviews focus primarily on findings from the quantitative research portfolio while in this paper
we describe the use of a novel surveymethodology that combines the use of both qualitative
and quantitative data.
Indonesia was chosen as the location for this research. It is the only country in the world
with three forms of LF present:Wuchereria bancrofti, Brugia timori and Brugia malayi. Indo-
nesia has participated in the GPELF since 2002, using Albendazole and Diethylcarbamazine in
yearly MDA to endemic districts. Across the archipelago, a variety of stages of the LF elimina-
tion programme exist–those completing mapping, some just beginningMDA, others moving
onto post-TAS surveillance and increasingly, more IUs are applying for TAS.
The process presented in this paper can be described as implementation research (IR). By
its design implementation research follows a systematic process that begins with close collabo-
ration between the research team, stakeholders and program implementers to identify a prob-
lem related to healthcare delivery and through research finds feasible solutions to improve
delivery and access [11]. This paper describes the development of a tool using micronarratives
to identify the bottlenecks related to LF drug delivery and drug uptake and the use of that sur-
vey to identify feasible recommendations for use in LF endemic communities in two endgame
districts in Indonesia. The research also describes how the district health offices used these rec-
ommendations in the implementation of an additional MDA round and how that impacted
reported drug coverage rates. Finally the implications of this research for LF elimination pro-
grammes with IUs in the endgame stages will be discussed.
Materials and Methods
Selection of the research sites
Following recommendations from the National LF Programme in Jakarta, two districts were
selected as research sites: Depok City and Agam District. Both sites had completed multiple
MDA rounds and were entering the endgame stage of their elimination programmes.
Depok City is part of the greater metropolitan areas known as Jabodetabek (Jakarta, Bogor,
Depok, Tangerang and Bekasi), which has a population greater than 28 million people, making
it one of largest metropolis areas in the world. Depok City is located inWest Java province,
with a population of 1.75 million in 2010. LF species in this area isW. bancrofti and the mf rate
was recorded as 1.83% (Ministry of Health Indonesia). In 2013, Depok City had completed five
rounds of MDA to the whole IU, with coverage rates varying between 46% and 84%, per dis-
trict calculations. In 2013, mf rates in the spot check and sentinel sites were 0% and the city
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health department applied to the National LF Programme to implement the TAS. They were
denied due to persistent low coverage below 65% in all five previous rounds, using standardized
census estimates as the source of total population data, and they were instructed to conduct a
further three MDA rounds.
Agam District is located on the western coast of Sumatra, roughly 1200 km from Banda
Aceh, site of the Boxing Day tsunami in 2006. In 2010, Agam had a population of just over
450,000 living in both urban and rural areas. LF species in this area is B.malayi and the mf rate
was 8.06% at the beginning of the elimination programme (Ministry of Health Indonesia).
Agam District conducted five MDA rounds by 2011 with an average epidemiological coverage
rate of 78.2% for the entire IU. The reported drug coverage for these five rounds ranged from
89.6% to 96.7% based on District Health Authority data. Therefore, based on the achieved cov-
erage rates for MDA in Agam and sentinel and spot-check site data assessed as<1%microfi-
laremia rates, the district qualified for a TAS in 2012. In total, 1315 students from 35 primary
schools in all 16 subdistricts were included in the sample. From these, 102 Brugia Rapid tests
were positive (from 28 primary schools) (Ministry of Health Indonesia). As a result, Agam Dis-
trict did not qualify to stop MDA and was required to continue MDA for an additional two
years (2013, 2014).
Questionnaire development
The survey tool developed during the course of this research was rooted in the use of a micro-
narrative or a brief story reflecting personal experienceswith the most recent MDA. Unlike
Knowledge, Attitudes and Practice (KAP) surveys, the majority of the survey questions related
to this specific experience or story. In order to solicit a story, the respondent was asked a spe-
cific ‘prompting’ question, like “Tell me what happened after you received the drugs for LF?”
Following the respondent’s story, a series of closed questions related to that specific experience
were asked, including details about the story participants, the location, the outcome (swallowed
the LF pills or not) as well as related emotions.
The micronarrative survey is based on the recognition that participation with MDA is a
social process, rather than a strictly individual one. As such, an individual’s direct and indirect
experienceswith the MDA and with the people associated with MDA will be most revealing
about how the implementation of MDA can be improved. One of the important advantages of
working with micronarrative is that it does not constrain the respondent to provide informa-
tion within a tightly prescribed framework of questions and answer options. Storytelling pro-
vides a mechanism to explore both expected and unexpected themes, using the respondent’s
personal experience as the reference point for subsequent closed questions. Because the use of
micronarrative combines the range and depth commonly seen in qualitative research method-
ologies with the accuracy and precision of cross sectional surveys, it offers a range of analytical
possibilities that will be explored in a subsequent publication.
Development of the survey tool was done together with stakeholders and health staff from
both districts. Through a series of workshops relevant themes known to be associated with
MDA outcomes were identified. The conceptual model used to guide this research used the
outcome of taking LF drugs (e.g. compliance) as a function of the interactions between the
deliverer, the endemic community member and the MDA setting itself. In actuality, two survey
tools were created–one to address the experiences of those involved in the drug delivery and
one for the endemic community member receiving the LF drug. This paper presents the survey
tool and results for the endemic community survey.
Prior to the baseline survey, the questionnaire was tested in Depok City with 40 community
members using enumerators from the Center for Health Research at the Universitas Indonesia
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in an area outside of the selected research sample. Changes to the questionnaires were made
based on this test. After the implementation of the baseline survey and prior to the start of the
endline survey, enumerators, the research team and the district health team provided inputs
for further refinement of the survey instrument. Some basic changes were made to the overall
format, however none of the outcome variables of interest were altered. The final survey tool
included the following components: socio-demographic information, a prompt to elicit a spe-
cific story related to the last MDA respondents participated in (e.g. “tell me what happened the
last time you were offered the LF drugs”), questions related to that experience (side effects, per-
son distributing the drug, reported drug taking behavior), and attitudes towards the MDA, the
LF drug, and the perceived drug taking behavior of the household and community.
Data collection
The EPI cluster survey design was used to calculate the number of clusters in each district (pro-
portionate to population size) for the endemic community surveys (n = 406 in each research
site). The sample size was calculated on the following criteria: an anticipated population pro-
portion of 90% with a confidence level of 95% and absolute precision of 5%. The required sam-
ple size for these parameters was 138 persons. From four previous similar LF surveys carried
out in Indonesia, the intra class correlation coefficientwas calculated as 0.235. Using a cluster
size of 7, the design effect for this surveywas set at 2.41. As a result, the necessary sample size
was 333 persons (138 x 2.41). A buffer of 20% was added in the event of refusals and/or incor-
rectly administered questionnaires. The total sample size required for the survey in each loca-
tion was 406 persons, or 58 clusters of 7 respondents. Henderson and Sundaresan (1982)
recommend a minimum of 30 clusters to ensure that the sample has a normal distribution
[12]. The basic sampling unit is the household, rather than the individual. Households were
randomly selected at the village level (throwing a pen and walking in the direction of the first
house). At the household level, one person was identified through a random selection of all
household members present at the time the enumerator visited. One person per household was
interviewed.Only those above the age of 15 years were included in the sample.
In both sites, locally based enumerators were selected and trained by Universitas Indonesia
researchers on the surveymethodology. All questionnaires were administered to respondents
by these trained enumerators. This sampling frame and methodologywas used for both the
baseline and endline surveys.
Data analysis
For both the baseline and endline surveys, data was double entered using Epi-Info and then
transferred for analysis to STATA 14. Data was checked for response bias, and range and con-
sistency checks were completed. Data was adjusted for the cluster effect and was weighted for
sex using district population statistics as a reference. Univariate and bivariate analysis informed
the construction of multivariable models for outcomes of interest that included: receipt of LF
drug, reported drug taking behavior (e.g. compliance) in the last MDA and previous drug tak-
ing behavior (e.g. history of having taken LF drugs during any MDA round). In the baseline
survey, a multivariable model testing the outcome of “compliance in the story” was done; this
model was not constructed in the endline survey. Backward elimination was applied to remove
factors from the model that were not significant at the level of 5%. Only the significant predic-
tors for each outcome were retained in the models. However age was selected a priori and
retained in each model regardless of its significance level. The adjustedWald test was used for
all multivariable models. This paper presents results from the closed questions in the survey.
The analysis of the micronarratives will be discussed separately.
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Analysis of the survey results for both the baseline and endline surveyswas done in close
collaboration with the district health authority in both sites. This process facilitated ownership
of the data and its results by those responsible for implementation of the MDA at the district
level. A wider range of stakeholders was consulted to discuss research findings and resulting
recommendations in a series of workshops in both locations.
Timing of the research
Prior to the start of the research, the last MDA round in Agam District occurred in November
2013 and the baseline surveywas conducted there in December 2013. In Depok City, the last
MDA round had been conducted in 2013, after which time the District health authority applied
for TAS and while waiting for the response ceasedMDA activities. The baseline surveywas
conducted in Depok City in January 2014; roughly one year after the last MDA was conducted.
Analysis of survey results was performed inMarch and April 2014. Presentation and discussion
of results at the district health offices was carried out in September 2014, followed by one tech-
nical visit to each site by one member of the research team to assist with the incorporation of
the research recommendations in the upcomingMDA. Flowcharts were developed for use by
drug distributors in both research sites and were finalized during the technical meetings.MDA
rounds in both locations were carried out in November 2014 and the endline surveyswere per-
formed in both locations within two months of the end of that MDA. Results were discussed at
a workshop with the district health authorities in June 2015 and presented to the National LF
Elimination programme in Jakarta.
Ethics statement
The Faculty of Public Health, Universitas Indonesia gave ethical clearance for both the baseline
and endline surveys. All questionnaires were anonymous and no personally identifying infor-
mation was collected. Informed consent from the respondent was obtained prior to the start of
the data collection. Eligible respondents were 15 years and above and each respondent gave
their own consent in writing to participate in the survey after being informed about the ques-
tionnaire, the time required for participation in the survey and understanding whom to consult
if there were any additional questions. At the end of the interview, survey respondents were
offered a small pencil case for their participation in the research and a leaflet on LF with Uni-
versitas Indonesia details, according to Indonesian ethical requirements.
Definitions used
Definitions related to persons receiving LF drugs and persons taking LF drugs vary significantly
in the peer reviewed literature and in the field [8–10]. In the reality of MDA, directly observed
treatment is not always implemented on the ground duringMDA, and as a result, theWHO defi-
nition of drug coverage may not always reflect the true rate of those who took the treatment.
Because of the heterogeneity of the definitions used, this research uses the following defini-
tions. Coverage is defined as the percentage of targeted persons who receive MDA medications
and compliance refers to theWHO definition for drug coverage, specifically, the percentage of
a targeted population who ingest the medication [8, 13].
Results
Characteristics of survey respondents in baseline and endline surveys
A total of 401 questionnaires were accepted for analysis fromAgamDistrict and 405 questionnaires
fromDepokCity in the baseline survey (n = 806). In the endline surveys, 405 questionnaires were
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accepted for analysis fromAgamDistrict, and 406 fromDepokCity (n = 811). Both rounds had
similar demographic distributions with the exception of occupation. There were more private
workers in the endline survey as compared to the baseline survey (Table 1). Housewives repre-
sented the highest proportion of professions recorded across all surveys (35% overall). Age distribu-
tion was similar betweenbaseline and endline survey rounds (p = 0.879) with 13% of respondents
under the age of 25 years, 24% between26–35 years, 25% between 36–45 years, 19% between 46–
55 years and 19% above the age of 56 years. Education was also similar across the two survey
rounds (p = 0.445) withmost respondents having completed secondary school (37%). Ten percent
had not completed primary school or had never attended school across all surveys.There were
some variations in demographics betweenDepokCity and Agam District in terms of education
level and occupations, but this was expecteddue to inherent urban and rural characteristics.
Both survey rounds had proportionately (relative to the population) more females in the
sample, likely due to the interview scheduled during the daylight hours in consideration of
security and logistical constraints. As a result, the sample was adjusted for gender for analysis
purposes. In addition the data was also adjusted for the effect of the cluster design. All data pre-
sented here use the adjusted results.
Baseline survey results
Respondents were asked in their narrative prompt to respond to the following question, “Ear-
lier you mentioned that you had received the LF drug duringMDA. Could you tell me about it,
what happened?” Most of the recorded stories were related to receiving and taking the LF
drugs (53%), receiving the drugs (28%) or taking the drugs (16%). A sample micronarrative
from a woman in her thirties in Agam District:
Table 1. Demographic characteristics of the sample in Agam District and Depok City.
Agam District Depok City
Baseline
unadjusted
Baseline
adjusted*
(n = 401)
Endline
unadjusted
Endline
adjusted*
(n = 405)
Baseline
unadjusted
Baseline
adjusted*
(n = 405)
Endline
unadjusted
Endline
adjusted*
(n = 406)
Male 96 (24%) 201 (50%) 103 (25%) 203 (50%) 91 (23%) 204 (50%) 61 (15%) 204 (50%)
Under 25 years 51 (13%) 52 (13%) 61 (15%) 65 (16%) 47 (12%) 53 (13%) 26 (6%) 37 (9%)
26–35 years 99 (25%) 92 (23%) 95 (23%) 85 (21%) 99 (25%) 93 (23%) 120 (30%) 122 (30%)
36–45 years 95 (24%) 104 (26%) 87 (21%) 89 (22%) 112 (28%) 105 (26%) 120 (30%) 106 (26%)
46–55 years 76 (19%) 68 (17%) 72 (18%) 65 (16%) 77 (19%) 77 (19%) 90 (22%) 89 (22%)
56 years and
above
80 (20%) 84 (21%) 91 (22%) 101 (25%) 66 (16%) 77 (19%) 50 (12%) 52 (13%)
Private worker 38 (9%) 59 (15%) 52 (13%) 72 (18%) 67 (17%) 101 (25%) 84 (21%) 165 (41%)
Informal worker 124 (31%) 164 (41%) 85 (21%) 116 (29%) 55 (14%) 70 (17%) 6 (1%) 21 (5%)
Housewife 188 (47%) 123 (31%) 212 (52%) 143 (35%) 225 (56%) 145 (36%) 277 (68%) 161 (40%)
Have not
completed
primary school
62 (15%) 60 (15%) 66 (16%) 72 (18%) 29 (7%) 20 (5%) 27 (7%) 16 (4%)
Completed
secondary school
203 (51%) 138 (35%) 221 (55%) 104 (26%) 251 (62%) 180 (45%) 276 (68%) 175 (43%)
Completed a
diploma /
university degree
36 (9%) 34 (9%) 24 (6%) 61 (7%) 78 (19%) 81 (20%) 64 (16%) 81 (20%)
*Adjusted for sex and clustering effect
doi:10.1371/journal.pntd.0005027.t001
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“In the morning, there was a general announcement from the mosque next door to my house
that there would be a drug distribution for filaria at the integrated health post (Posyandu).
When I got there, the midwife asked me how old I was, and then she gave me the drug and
told me to take it before going to sleep. So I went home, and at night that day, I took the
drugs.”
Half of the survey respondents reported that they had received LF drugs from a community
health worker (50%) whilst over a quarter received LF drugs from a family member, friend or
neighbor (27%). Sixty-three percent reported that they took all of the pills they were given
while 8% reported that they took only some of the pills. Most respondents indicated “myself ”
as the greatest influence on their decision to take the pills (77%), followed by the health worker
and community health worker (10%). Nearly half (49%) reported no side effects after taking
the treatment.
Women were less likely than men (AOR = 0.53) to have complied with treatment in the last
MDA (p = 0.011). Predominant reasons for noncompliance in the last MDA included being
pregnant (4% of total noncompliers), too old (4%), sick at the time of distribution (17%), taking
other drugs (12%) and lack of information (19%). In the Indonesian eligibility guidelines for
MDA at the time of the baseline survey, breastfeedingwomen and people above the age of 65
years were excluded from treatment.
Specific questions related to the last MDA included: where the LF drugs were received,
awareness about MDA, knowledge of other family members’ compliance with MDA and one
question related to knowledge of the cause of LF. In Agam District, 71% of respondents were
aware of the MDA before it occurred, compared to 67% in Depok City. Most people in Agam
District received the LF drugs inside their homes (79%) confirming the house-to-house distri-
bution method preferred in this area. In Depok City, 56% of respondents received their LF
drugs inside their house reflecting the higher use of distribution posts here due to the high pop-
ulation density, presence of apartment buildings and the mobile nature of an urban population.
Respondents were asked if they knew of anyone else in their household who had complied with
the LF drugs: in Agam District 75% knew someone in their household, compared with 69% in
Depok City. In both locations, around a quarter of respondents identifiedworms (22% in
Agam District; 25% in Depok City), and mosquitoes (31% in Agam District; 48% in Depok
City) as the cause of LF.
Respondents were asked some attitudinal questions about MDA and LF drugs. In Agam
District, more respondents cited that LF drugs were safe (73%), compared to Depok City
(62%). However in both research locations, a majority of respondents believed that MDA was
very important for their health (85% in Agam District and 77% in Depok City).
Multivariable logistic regression models were created for four key outcomes of interest
(Table 2): ever complied with LF drugs, ever received LF drugs, reported compliance in the last
MDA offered and reported compliance described in the story.
Data from the baseline surveys showed that 19% of respondents in Agam District and 24%
of respondents in Depok City had never received the LF drugs during any MDA. In the multi-
variable model (after adjusting for district, education, income and occupation) age and sex
were determined to have had an effect on whether or not respondents had ever received the LF
drugs. Overall, women were three times more likely to receive the LF drugs as compared to
men (AOR = 3.02; p = 0.001). This may reflect the distribution strategies used in both sites
whereMDA was conducted primarily during the day. Respondents aged 15–25 years were the
least likely to receive the LF drugs as compared to respondents aged above 26 years. Those
aged between 46–55 years were 7 times more likely to have ever received the LF drugs as com-
pared to respondents aged 14–25 years (AOR = 7.38; p = 0.001).
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Table 2. Multivariable models for Baseline survey (2014)^.
Unadjusted values Adjusted values
N OR (95% CI) P-value AOR (95% CI) P value
Ever received LF drugs during MDA (N = 804)
Sex
Male 405 1.00 1.00
Female 399 2.56 (1.7–3.9) <0.001 3.02 (1.7–5.5) 0.001
Age**
15–25 years 103 1.00 1.00
26–35 185 1.92 (1.0–3.7) 0.050 2.20 (1.0–4.7) 0.041
36–45 209 3.12 (1.6–5.9) 0.001 3.94 (1.8–8.7) 0.001
46–55 146 5.67 (2.3–14.3) <0.001 7.38 (2.5–21.9) 0.001
56+ 159 2.12 (1.2–3.8) 0.013 2.82 (1.2–6.7) 0.019
Ever taken LF drugs (N = 631)
Location
Agam 323 1.00 1.00
Depok 308 0.40 (0.3–0.7) <0.001 0.36 (0.2–0.7) 0.003
Perceived safety of the LF drug 631*
Yes, drugs are safe 1.00 1.00
No, not safe 0.55 (0.4–0.7) <0.001 0.60 (0.5–0.8) <0.001
Knows another household member who took LF drugs**
Yes 456 1.00 1.00
No 148 0.17 (0.1–0.3) <0.001 0.18 (0.1–0.3) <0.001
Don’t remember 26 0.37 (0.2–0.9) 0.036 0.30 (0.1–0.9) 0.024
Location where drugs were received**
Inside the house 429 1.00 1.00
Outside the house 164 1.68 (1.0–2.8) 0.047 2.74 (1.4–5.4) 0.004
Media stories were informative and helpful
No 289 1.00 1.00
Yes 342 2.02 (1.4–2.9) <0.001 2.10 (1.3–3.3) 0.002
Compliance in the last MDA (N = 631)
Sex
Male 287 1.00 1.00
Female 344 0.90 (0.6–1.3) 0.579 0.53 (0.3–0.9) 0.011
Perceived importance of LF drugs for health** 629*
Yes 1.00 1.00
No 0.55 (0.4–0.7) <0.001 0.62 (0.5–0.8) 0.002
Perceived safety of drugs** 625*
The drugs are safe 1.00 1.00
No, the drugs are not safe 0.53 (0.4–0.7) <0.001 0.60 (0.5–0.8) <0.001
Health status in the last MDA e.g. taking other medications at the time of MDA**
Not taking other drugs 570 1.00 1.00
Yes, taking other drugs 58 0.13 (0.1–0.3) <0.001 0.12 (0.1–0.3) <0.001
Never taken LF drugs before**
Has taken LF drugs before 375 1.00 1.00
Never taken LF drugs before 238 0.29 (0.2–0.4) <0.001 0.37 (0.2–0.6) <0.001
Reported compliance in the story (N = 631)
Location**
Agam 322 1.00 1.00
(Continued )
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In the questionnaire, respondents were asked if they had ever taken the LF drug during any
MDA offered in the past. Nearly 62% of those who had ever received the drugs had a history of
compliance in both research sites, meaning that 38% of those who had been offered the LF
drugs had never taken them. These individuals, called systematic noncompliers, can be defined
as people who persistently refuse or do not ingest the antifilarial medications over the course of
an MDA program [8]. Systematic noncompliers may harbor LF infection and have the poten-
tial to contribute to LF resurgence [14, 15]. Factors related to systematic noncompliance in our
study included the perception that the LF drugs were unsafe (AOR = 0.6; p<0.001) and not
knowing anyone in the household who had taken the LF drugs (AOR = 0.18; p<0.001). Positive
associations with a history of having taken the LF drugs included being given the LF drugs out-
side of the house (AOR = 2.74; p = 0.004) and perceivingmedia stories to be informative and
helpful (AOR = 2.10; p = 0.002).
For compliance in the last MDA, the multivariable model was stratified by location to eluci-
date if there were differences between the urban (Depok City) and rural (Agam District) data-
sets. As discussed earlier, the surveywas conducted within one month of the last MDA in
Agam District, and more than one year after the last MDA in Depok, so we anticipated some
Table 2. (Continued)
Unadjusted values Adjusted values
N OR (95% CI) P-value AOR (95% CI) P value
Depok 308 0.45 (0.3–0.7) 0.001 0.44 (0.2–0.8) 0.009
Sex**
Male 286 1.00 1.00
Female 344 0.86 (0.6–1.3) 0.435 0.48 (0.3–0.9) 0.015
Aware of MDA prior to drug distribution
No 60 1.00 1.00
Yes 571 1.61 (0.9–2.8) 0.097 2.59 (1.0–6.7) 0.048
Perceived common good as reason for compliance**
No 326 1.00 1.00
Yes 304 2.69 (1.8–3.9) <0.001 1.50 (1.1–2.1) 0.019
Perception of taking LF drugs to be healthy
No 122 1.00 1.00
Yes 509 14.05 (6.9–28.8) <0.001 10.74 (5.1–22.6) <0.001
Fear of side effects
No 539 1.00 1.00
Yes 92 0.28 (0.2–0.4) <0.001 0.24 (0.11–0.5) <0.001
Because other people took the drugs
No 542 1.00 1.00
Yes 89 3.08 (1.5–6.4) 0.003 2.27 (1.1–4.7) 0.030
Influence of the drug packaging
No 556 1.00 1.00
Yes 75 2.56 (1.3–5.2) 0.010 1.88 (1.0–3.5) 0.048
Influence of the level of information received** 629*
No 1.00 1.00
Yes 1.24 (1.1–1.4) 0.004 1.28 (1.1–1.6) 0.014
^Variables with p<0.05 were included in the final models.
*Denotes continuous variable
**Missing values.
doi:10.1371/journal.pntd.0005027.t002
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differences due to recall of events. The following variables were associated in these analyses. In
Depok City, (1) age was not a factor associated with compliance; (2) Working in the private
sector had a lower odds for compliance than those who were unemployed (p = 0.006); (3) The
perceived importance of LF drugs for health positively influenced drug taking behavior
(p = 0.02); (4) Past history of compliance was seen as an important influence, e.g. if respon-
dents had never taken the LF drug, then they were less likely to comply in the last MDA
(p = 0.002). In Agam District specifically: (1) Those who were 26–35 years were less likely to
comply in the last MDA than the 15–25 year old group (p = 0.013); (2) Working in the private
sector had a higher odds for compliance than the unemployed (p = 0.02); (3) Perceived good
drug safety positively influenced the decision to comply in the last MDA (p = 0.004).
In the multivariable model for reported compliance in questions related to the story
(adjusted for district, age, income, education and occupation) several factors were associated
with taking the LF drug. In the stories, the value of “being healthy” had a strong positive influ-
ence on compliance. Those reporting that being healthy was an important influence on their
decision to take LF drugs were nearly 11 times more likely to report compliance in their stories
than those who did not cite “being healthy” as an influence (AOR 10.74; p<0.001). Perceived
common good (AOR 1.5; p = 0.019) had a positive influence on compliance, suggesting respon-
dents understood the norm that taking LF drugs benefits the community. This social norm of
compliance was also seen in the positive influence of knowing others had taken the treatment
in the stories. Those who reported that others taking the LF drugs influenced their own behav-
ior were 2.27 times more likely to report their own compliance in their stories (AOR 2.27;
p = 0.030).
Women were less likely than men to have taken the LF drugs in the last MDA (AOR = 0.53;
p = 0.011) as well as in the MDA experiences they described (AOR = 0.48; p = 0.015). Preg-
nancy and breastfeeding (considered as contraindicated in some Indonesian districtMDAs)
may explain why women were less likely to comply.
Recommendations for implementation of next MDA round in 2014
After the results were compiled, a series of workshops were held to discuss the results with the
District Health teams and to present the findings to relevant stakeholders in both districts and
at the national level. Feasible actions to address issues related to coverage and compliance were
identifiedwith program personnel from each location. In addition to the workshops, prior to
the start of MDA awareness activities in each site, one member of the research team gave a
brief technical visit to further discuss the survey results with stakeholders and other district
health staff.
In order to improve distribution of LF drugs duringMDA in both areas, the primary groups
that neededmore targeted attention were men and youths between the ages of 15–24 years. At
the time of the MDA, women were successfully receiving the drugs in both areas with the dis-
tribution strategies in place. In order to widen the reach and to increasemen’s participation, it
was recommended to consider an approach to MDA that would occur simultaneously at
schools, government and private offices, households as well as factories. In order to reach
younger persons, use of social media and text messaging were suggested.
For those who had never complied with taking the LF drugs in the past (considered as sys-
tematic noncompliers), the findings suggest that they were also unlikely to comply in future
MDA rounds, thus continuing their pattern of behavior. As such, it was recommended to
develop a method to identify these persons at the start of the drug delivery encounter so that
the drug distributors could target them with specificmessaging. A flow chart of questions was
created for the drug distributors to use. It began with the question, “When was the last time
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you took the LF drugs duringMDA?” Subsequently, the distributor was prompted through a
series of questions and responses to aid them in persuading this person to accept LF drugs. As
media stories considered as positive and helpful were seen to be associated with compliance, it
was recommended to have an intentional media campaign, if possible emphasizing the social
norm of compliance, e.g. “I took it with the other people in my family, neighborhood, city.”
Another issue that was identified through the baseline surveywas the ineligibility criteria
used by drug distributors duringMDA. Individuals taking other medications at the time of
MDA (namely for hypertension and diabetes), those over the age of 65 years and breastfeeding
women were frequently excluded from treatment. It was recommended to the national LF pro-
gram to increase the upper age limit for MDA eligibility and reinforce the international guide-
lines regarding exclusion. In addition, messages about drug safety should be used to help
promote trust and reduce fear of side effects for communities.
Baseline data revealed that perceived drug safety, number of pills and packaging of LF drugs
had an important influence on the decision to swallow the pills. As a result, it was suggested to
package the pills with specificmessages addressing the following: drug safety (“# million people
in Indonesia safely took LF drugs last year”); drug-takingprocedure (“take all the drugs at
once, preferably with a meal”); ineligibility information (children under 2 years, pregnant
women and severely ill persons); benefits of compliance for yourself, your family and commu-
nity and finally where to go if you need assistance.
Finally in terms of messaging surrounding the next round of MDA, it was recommended
that the district health authorities focus their messages on the social norm of compliance (e.g.
“everybody is doing it”) and on the safety of LF drugs globally and in Indonesia. It was sug-
gested that messaging regarding side effects continue to be used, with a focus on promoting the
message that side effects indicate that the medicine is working. Ancillary benefits to treatment
regarding the elimination of intestinal helminthes should also be promoted, particularly in
Agam District. Finally MDA should be promoted as a preventive activity, rather than a treat-
ment (“taking it will keep you healthy”). This would counteract the argument some community
members made that they were not sick, so therefore did not need to take LF drugs.
Actions taken by the district health authorities in the 2014 MDA
Because the remit of this project at the outset was primarily to design and test an effective
research tool, there was no budget available to assist the districts with their MDA operations.
Furthermore, the research team did not monitor the planning or execution of MDA in either
site. Both research sites followed through on many of the discussed recommendations, as
describedhere.
In Agam District, the district health office was able to secure additional funding from the
local government to implement the twoMDA rounds they were requested to complete. Note
that with decentralizedhealth financing in Indonesia, many districts are required to fund the
operational costs for LF elimination themselves. Based on the recommendations of this study,
the district health office in Agam retrained the 4000 community health workers responsible for
drug distribution. Promotional media was used, including stickers on government vehicles,
additional production of leaflets as well as banners. Prior to 2014, schools had never been
approached to aid in the promotion of MDA. After interpreting the baseline survey results
with the district health team, teachers were provided with the flowcharts produced by the proj-
ect. These flowcharts aided teachers in promoting the drug distribution by guiding them to ask
their students if they had taken their LF drugs after the recent MDA. In an attempt to better
reach men, the district team worked with local factories, distributing the drugs during working
hours after securing consent from the factorymanagement.
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Depok City was unable to secure additional local financing for its repeatedMDA rounds. As
a result the head of the program used every opportunity to integrate LF promotional and edu-
cational messages into existing activities. In most district health meetings, the LF program pro-
motes the MDA to those stakeholders present. Using existing primary health care center funds,
community health workers participated in “refreshing” activities prior to MDA, where previ-
ous training was reviewed.New stakeholder groups were approached, specifically police and
army barracks located in the city, private and public hospitals, the Indonesian Association of
Midwives, the Indonesian Doctors Association as well as local NGOs to promote and facilitate
MDA. In terms of additional promotional activities, a running text billboard ran messages one
month prior to the start of MDA and a radio show integrated LF messages into their regular
programming. A number to call or text questions was posted and promoted so that the com-
munity members could present concerns to the health team. Finally, a small leaflet was pro-
duced for inclusion with the drug packages. This provided point of contact information for the
drug recipients on how to take the pills. Health staff and community health workers were pro-
vided with a Frequently Asked Question (FAQ) sheet to aid with drug distribution.
Endline survey results
The three primary outcome variables related to compliance showed a marked improvement in
the endline surveys relative to the baseline surveys (Table 3). Of those who had ever received
LF drugs, Agam in particular showed a marked increase from 81% to 100% of those surveyed.
This indicates that Agam District was able to reach significant numbers of new individuals
who had never received LF drugs in previous MDA rounds. Specifically this represented an
increase in drug receipt across all age ranges, with the highest being a 40% increase for those
under the age of 25 years, one of the key target groups identified in the baseline survey.
For those who reported a history of taking LF drugs in the past, the most prominent change
was seen in Depok, from 72% in the baseline to 88% in the endline survey. This represents an
increase in the uptake by first time compliers. For the total sample, the change in compliers
went from 79% in the baseline to 90% in the endline survey, of those who had ever received LF
drugs. Table 3 provides the summary of results of key outcome variables for both baseline and
endline surveys.
Table 3. Comparison of baseline and endline results.
Agam District Depok City Total
Baseline Endline Baseline Endline Baseline Endline
N = total sample
Have ever received the LF drug during MDA 80.6% 100%* 76.3% 76.9% 78.4% 88%*
N = individuals who had ever received LF drugs during MDA
Have ever taken the LF drug during MDA 86.1% 92.1%* 72.3% 88.1%* 79.3% 90.4%*
Received LF drug during last MDA 68.7% 90.8%* 69.7% 73.8% 69.2% 82%*
Took the LF drug in the last MDA 66.6% 84.1%* 48.2% 67.3%* 57.3% 77%*
Aware of MDA before receiving drugs 71% 85.8%* 67% 85.6%* 69.1% 85.7%*
Knew someone in the house that had taken LF drugs 75% 84.6%* 69.4% 81.9%* 72.3% 83.5%*
LF drugs perceived as safe 73% 71.9% 62% 66.9% 67.62% 69.79%
Taking LF drugs perceived to be important for health 85% 86.4% 76.8% 88.9%* 81.0% 87.5%*
Reported to have swallowed all of the LF drugs at once 71.6% 82.1%* 53% 66.7%* 62.5% 75.4%*
Not having enough information as the reason cited for noncompliance 18.5% 14.8% 19.9% 8.6% 19.4% 10.9%
*Change in percentage where p<0.05
doi:10.1371/journal.pntd.0005027.t003
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Respondents were asked about their participation in the last round of MDA. Agam District
increased the proportion of those receiving LF drugs in the last round by 32% while Depok
City’s improvement was 6%. The change in those reported to have taken the drugs in the last
MDA was more marked in Depok City from 48.2% in the baseline round to 67.3% in the end-
line round, representing a 40% improvement between the two survey rounds. In Agam the
change was from 66.6% to 84.1%, representing an improvement of 27% for compliance in the
last MDA.
Other changes between baseline and endline datasets included key indicators related to the
recommendations that were given prior to the 2014 MDA. Awareness of MDA prior to drug
distribution increased in both sites, as did the awareness of someone taking the treatment in
the household. The message to take all of the pills at the same time appears to have been well
communicated in both research locations with a marked improvement from 63% to 75%
(p<0.001) overall.
In the multivariable analysis (Table 4), some factors remained strongly associated with com-
pliance as seen in the first survey round. In the multivariable model for compliance in the last
MDA, perceived importance of LF drugs for health continued to be strongly associated with
compliance (AOR 42.76; p = 0.001). Similarly those who believed that LF drugs were safe were
3.7 times (AOR) more likely to comply in the last MDA round than those who perceived the
drugs as dangerous (p = 0.027). As in the baselinemodels, those who did not know anyone else
in their household who took the drugs were less likely (AOR 0.16) to comply in the last MDA
round than those who did (p<0.001).
In addition, some new factors emerged that were associated with compliance. In the model
for compliance in the last MDA, length of stay in the region less than two years was associated
with higher odds of compliance than those who had lived in the area for more than two years
(p = 0.001). Additionally those who did not know a cause of LF were less likely to have com-
plied in the last round of MDA (AOR 0.25; p = 0.005) than those who knew that worms caused
the disease in the body.
In the model for “having ever taken LF drugs” some new factors emerged as well. In terms
of the identity of the drug distributor, respondents who knew the drug deliverer were more
likely to comply compared with those who did not know the deliverer (p = 0.001). External
influence on the decision to comply remained strong. Respondents who cited an external influ-
ence on their decision to comply were 2.6 times (AOR) more likely to have ever taken LF drugs
compared to those who reported no outside influence (p = 0.034).
Table 5 summarizes the key factors that were positively associated with complying with the
LF treatment from both the baseline and endline surveys.
Discussion
This research demonstrates that both drug distribution and ingestion of pills by the community
can be improved when the issues affectingMDA delivery are identified using appropriate tools
and processes and then are acted upon by the district health teams. The delivery of MDA was
assessed in two research sites in Indonesia where there had been a history of insufficient cover-
age rates and persistent LF transmission. Post-MDA baseline surveyswere conducted in
endemic communities in late 2013, early 2014 in both districts. Based on the results of those
surveys, the district health teams worked together with the research team to identify feasible
recommendations to apply to their 2014 MDA programs. The research team did not provide
any supplemental funds for MDA operations and both districts were responsible for imple-
menting the identified recommendations. Results from the endline survey conducted shortly
after the 2014 MDA showed that there was a marked improvement in coverage and compliance
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Table 4. Multivariable models for Endline survey (2015)^.
Unadjusted values Adjusted values
N OR (95% CI) P value AOR (95% CI) P value
Ever received LF drugs during MDA (N = 811)
Age
15–25 years 99 1.00 1.00
26–35 208 1.96 (0.8–4.65) 0.128 2.12 (0.8–5.3) 0.107
36–45 195 3.21 (0.9–10.6) 0.056 3.22 (1.1–9.1) 0.028
46–55 155 4.09 (0.9–16.8) 0.05 4.47 (1.2–16.2) 0.023
56+ 154 2.02 (0.6–6.5) 0.237 1.68 (0.6–4.4) 0.291
Occupation
Housewife 304 1.00 1.00
Private 237 0.29 (0.1–0.6) 0.002 0.28 (0.1–0.6) 0.002
Informal 137 3.51 (0.6–20.9) 0.166 3.74 (0.7–20.1) 0.123
Other 133 0.35 (0.1–0.9) 0.029 0.57 (0.2–1.3) 0.196
Ever taken LF drug (N = 717)
Location
Agam 405 1.00 1.00
Depok 312 0.64 (0.3–1.2) 0.148 0.44 (0.2–1.0) 0.056
Age
15–25 years 77 1.00 1.00
26–35 181 0.30 (0.1–0.9) 0.038 0.19 (0.0–1.2) 0.082
36–45 179 0.37 (0.1–1.1) 0.061 0.07 (0.0–0.4) 0.006
46–55 145 0.77 (0.2–2.5) 0.652 0.16 (0.0–1.2) 0.078
56+ 135 0.4 (0.1–1.4) 0.157 0.15 (0.0–1.2) 0.075
Income**
Less than minimum wage 350 1.00 1.00
Equal to or more than minimum wage 338 0.68 (0.3–1.5) 0.330 0.23 (0.1–0.7) 0.007
Perceived safety of drugs
Dangerous 45 1.00 1.00
Neutral 172 5.00 (1.8–13.9) 0.002 3.66 (1.0–13.4) 0.050
Safe 500 21.56 (8.3–56.4) 0.000 6.33 (1.7–22.9) 0.005
Aware of MDA prior to drug distribution
Yes 614 1.00 1.00
No 103 0.29 (0.1–0.7) 0.003 0.30 (0.1–0.8) 0.020
Perceived importance of LF drugs for health
Unimportant for health 21 1.00 1.00
Neutral 69 13.77 (3.1–60.8) 0.001 23.04 (3.7–142.6) 0.001
Important for health 627 67.01 (14.7–305.6) 0.000 42.63 (7.2–252.6) <0.001
Influencing the decision to comply**
Myself (no outside influence) 423 1.00 1.00
Others 288 3.34 (1.6–7.2) 0.002 2.65 (1.1–6.5) 0.034
Knows the deliverer
Yes 640 1.00 1.00
No 77 0.22 (0.1–0.5) 0.001 0.18 (0.1–0.5) 0.001
Knows another household member who took LF drugs
Yes 598 1.00 1.00
No / Don’t know 119 0.07 (0.03–0.2) <0.001 0.11 (0.0–0.3) <0.001
Possible negative or positive effects of MDA on health**
(Continued )
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as well as in other key indicators. The baseline and endline surveys described in this research
used a novel approach–asking people to recount their experienceswith MDA in micronarra-
tives. These stories provided the foundation to assess MDA programs through the perspectives
of the people expected to ingest the LF drugs. The effectiveness of the micronarrative survey
combined with the close collaboration with the district health teams has been shown in the
overall improvement of drug delivery and compliance.
Table 4. (Continued)
Unadjusted values Adjusted values
N OR (95% CI) P value AOR (95% CI) P value
Less important 219 1.00 1.00
Important 265 1.70 (0.5–5.4) 0.362 1.37 (0.3–5.5) 0.656
Very important 214 0.21 (0.1–0.5) 0.001 0.27 (0.1–0.8) 0.019
Compliance in the last MDA (N = 665)
Location
Agam 365 1.00 1.00
Depok 300 0.39 (0.2–0.7) 0.001 0.26 (0.1–0.5) <0.001
Age
15–25 years 70 1.00 1.00
26–35 166 0.51 (0.3–1.0) 0.060 0.60 (0.2–2.0) 0.401
36–45 174 1.05 (0.5–2.1) 0.885 1.26 (0.4–4.2) 0.711
46–55 134 1.93 (0.9–4.2) 0.096 3.76 (1.0–13.6) 0.044
56+ 121 1.42 (0.6–3.5) 0.440 3.06 (0.7–13.4) 0.135
Perceived importance of LF drugs for health
Unimportant for health 21 1.00 1.00
Neutral 57 11.03 (1.2–98.6) 0.032 30.83 (3.6–263.9) 0.002
Important for health 587 34.01 (3.9–296.8) 0.002 42.76 (4.8–380.4) 0.001
Perceived safety of drugs**
Dangerous 42 1.00 1.00
Neutral 156 2.59 (1.0–6.6) 0.045 1.74 (0.5–5.9) 0.370
Safe 466 8.07 (3.1–20.8) <0.001 3.73 (1.2–11.9) 0.027
Cause of LF**
Worms 126 1.00 1.00
Mosquitoes 230 0.81 (0.4–1.5) 0.494 0.56 (0.2–1.3) 0.187
Don’t know 257 0.37 (0.2–0.8) 0.016 0.25 (0.1–0.6) 0.005
Other 29 0.75 (0.3–2.3) 0.615 0.42 (0.1–1.6) 0.204
Possible negative or positive effects of MDA on health**
Less important 199 1.00 1.00
Important 251 1.31 (0.6–3.1) 0.529 1.02 (0.5–2.2) 0.960
Very important 200 0.29 (0.1–0.6) 0.001 0.42 (0.2–0.9) 0.016
Length of stay in the survey district
<2 years 30 1.00 1.00
2+ years 635 0.66 (0.2–2.2) 0.499 0.06 (0.01–0.3) 0.001
Knows another household member who took LF drugs
Yes 565 1.00 1.00
No 100 0.10 (0.1–0.2) <0.001 0.16 (0.1–0.3) <0.001
^Variables with p<0.05 were included in the final models.
**Missing values.
doi:10.1371/journal.pntd.0005027.t004
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As the 2020 elimination goal approaches, increasingly districts will reach the transmission
assessment process and post-MDA surveillance period. The decision to begin these processes
will be made based on the reported drug coverage data submitted by the implementation units
(IUs). For programs where directly observed treatment (DOT) is not routinely used, distrib-
uted drugsmay not necessarily be consumed. As a result, reported drug coverage rates will
reflect distributed drugs as opposed to ingested drugs. Because of this coverage-compliance gap
[9] in reporting, it is possible that transmission assessment surveys (TAS) may begin prema-
turely in some areas [16].
For implementation units where reported drug coverage rates are sufficient over the course
of the MDA rounds, the IU will qualify for TAS. The district health personnel approach the
first steps of TAS hopeful of an outcome that will allowMDA to stop. However if TAS reveals
ongoing LF transmission, then the district must agree to continue administering additional
MDA rounds as per the international guidelines [13]. Reasons for ongoing LF transmission are
varied, including evidence that significant levels of noncompliance with taking LF drugs can
maintain a reservoir of LF infection [14, 15]. This level of noncompliance may be due to indi-
vidual behavior, drug distribution issues or misclassification in reporting. It is important to
note that health staff may not be aware of the coverage-compliance gap in their own reporting
and so a “negative” result in the first round of the TAS can come as a surprise. In both Agam
District and Depok City, district health staff reported feeling discouraged and confused by pre-
TAS and TAS results that indicated additional MDA rounds were required.
Because of decentralizedplanning and funding in Indonesia, the district health staff in both
study areas were required to request more resources from district government budgets in order
to carry out these unscheduled additional MDA rounds. With this, success in future MDA
rounds became of paramount importance. In order to ensure improved coverage in subsequent
MDA rounds, the district LF programs needed input and guidance to understand the real
impact of their past MDA activities–what groups were missed; where should attention be
Table 5. Summary of factors positively associated with taking the LF treatment.
Ages 36–45 years^; 46–55 years^
Male*
Earns less than the monthly minimum salary^
Lives in the area less than 2 years^
Not taking other medication at time of MDA*
Takes LF drugs before*
Knows the deliverer^
Receives the drugs outside of the house*
Knows another household member who took LF drugs*^
Aware of MDA prior to distribution*^
Media stories are informative and helpful*
Perceives LF drugs to be safe*^
Perceives importance of LF drugs for health*^
Perceives the common good as a reason to take the LF drugs*
Not afraid of side effects*
Because other people took the LF drugs*
Influences others to take the LF drugs^
*Baseline survey
^Endline survey
doi:10.1371/journal.pntd.0005027.t005
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focused;what had worked; what needed improvement? This research provides a systematic
process and innovative data collection tool to district or national programs to help them gain
perspective on their operational MDA from the perspective of both the community and the
drug distributor.
One of the primary aims of this research was to test the acceptability and feasibility of a
novel methodology–themicronarrative survey–as applied to the MDA environment. Unlike
routine coverage surveys, the tool developed in this research provided a deeper understanding
of the MDA, beyond questions of drug receipt, drug compliance and knowledge about LF, to
eliciting people’s direct experienceswith the program. In this context, the micronarrative sur-
vey proved to be a powerful tool to reveal themes that were associated with influencing compli-
ance. Some of the factors identified through this research are new and further our
understanding of why people swallow the LF drugs; while other findings echo factors from
research in other global studies.
Some of the themes associated with coverage and compliance detected in this research are
consistent with results from other studies, contributing to the potential of this methodology to
identify why people receive and take LF drugs (and why they do not). For example, advanced
knowledge of the MDA before drugs were distributed was an important factor associated with
compliance in this research, echoing results frommany programs in both the Asian and Afri-
can regions [8, 17]. Perceived poor safety of the LF drugs was shown to have a negative effect
on compliance in both the baseline and endline surveys, revealing a lack of trust in the pro-
gram. The lack of trust or misconception about the MDA program has been cited as an attitude
associatedwith low compliance in a recent systematic review in India [9]. In the endline survey,
respondents who did not know their drug distributor or trust them were less likely to have
received LF drugs in the last MDA. Similarly results from Sri Lanka have shown that compli-
ance is positively affected when the community knows their drug distributor [18] and con-
versely in India low acceptability of the drug distributor was determined to have a negative
effect on compliance [19].
This research identified two groups who were less likely to comply with LF treatment:
females and the youngest age group (15–25 years). A study from Egypt also identified that
beingmale as well as having older age were both positively associated with compliance [20];
while research in Haiti demonstrated systematically low compliance rates in women [21]. In
Indonesia, the national LF programme originally recommended that breastfeedingwomen
should be considered as ineligible for MDA; however this position has recently changed. These
changes to eligibility criteria can take time to filter down to the drug distributor where they are
operationalized.
Throughout each step of the process of implementation research, from identifying the
important issues related to MDA, to designing the survey tool and reviewing the results, the
research team worked closely with district health staff from both Agam District and Depok
City. This process fostered ownership of the data and its results, both positive and negative.
Through the various workshops, both district health teams had multiple opportunities to share
their own experiences and challenges as well as their own best practices with each other. This
exchange empowered both teams to enact change rather than react defensively when faced
with the research results.
By reviewing the baseline survey results together, the district health staff was able to discern
which operational recommendations would be feasible within their own contexts and existing
district health budgets. Some of the actions based on the baseline results that were used in the
districts included: (1) an approach to MDA that occurs simultaneously in several locations
(schools, government offices, factories); (2) the use of social media to reach younger people; (3)
engaging teachers and schools to promote MDA and compliance with MDA; (4) reinforcing
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messages that LF drugs are safe and that the combination of drugs received duringMDA
should be taken all at once; (5) encouraging directly observed treatment; (6) utilizing drug
packaging as an opportunity to inform people; (7) promoting messages that encourage the
social norm of compliance e.g. “everyone is taking it”; (8) promoting messages that reinforce
the positive healthy impacts of LF treatment, lessening the primary emphasis on side effects;
(9) ensuring that the community is aware of MDA before it begins; (10) aiding the drug distrib-
utors to address key questions arising from the community and to identify never compliers at
the start of the drug distribution encounter.
Both research areas adapted these recommendations to their local contexts and were able to
significantly improve the coverage and compliance in their addedMDA rounds. For Agam, the
most significant change was the shift from 80% at baseline to 100% coverage (e.g. drug receipt)
by surveyed community members in the endline survey. This change represents new people
who were reached in the 2014 MDA, most likely the result of improved drug distribution
efforts using schools and factories for the first time. For Depok, overall distribution to eligible
persons between the two rounds remained mostly unchanged; however district efforts resulted
in an increase of first time compliers who took LF drugs for the first time during the 2014
MDA. This was likely accomplished through the wide scale integrated approach that the pro-
gram used to reach new community members, stakeholders and key groups.
These study results are promising in a few key areas. They show that LF program personnel
at the district level when provided with relevant information have the influence and willingness
to alter their MDA so as to improve both coverage and compliance. It cannot be assumed that
district programs always have the support and information that they need to adequately
address deficiencies in their MDA delivery and in some contexts, a more targeted approach
may be required. Although this specialized technical support at the district (IU) level seems
expensive and unsustainable given the scope of the global LF elimination program, it has the
potential to make a significant impact. In twelve months, the two LF programs involved in this
research were able to make substantial changes to their MDA delivery without additional fund-
ing using a deeper understanding of their MDA to guide the necessary changes. Although
beyond the remit of this research, understanding the long term cost savings of implementing a
more tailored approach to MDA as describedhere may have important implications for the
global LF elimination programme in terms of costs averted from failed TAS and additional
MDA rounds.
Finally, the novel micronarrative research tool, which focused on collecting people’s experi-
ences with the MDA program, was shown to be capable of producing valuable insights into fac-
tors associated with coverage and compliance that were then translated into action with a
measurable impact on program goals. Much of the social research related to LF elimination in
the past has focused on questions of knowledge, attitudes and practice (KAP). Compliance
with LF is a social activity, whether taken publicly at a distribution post or at the dinner table.
The importance of these social influences is often not captured in routine KAP and coverage
studies. As a result, promotion of MDA has tended to focus on increasing knowledge at the
individual level as opposed to generating a social movement in the community to eliminate a
disease and to promote health. This tool has demonstrated the value and potential of taking
social research about health behavior (in this case receiving and ingesting LF drugs) outside of
the narrow realm of KAP into one where the aim is to understand what has happened to people
and how those experiences shape the decisions they make. That said, the scope of this tool and
process could be applied to other areas, outside of LF elimination, to explore people’s experi-
ences with other questions of drug adherence, the evaluation of health service provision, or
monitoring and evaluation of new initiatives or tools.
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Limitations
There are some the limitations in our research that are worth noting. The EPI methodology
when applied to the context and combined with the logistical constraints in Agam District and
Depok City resulted in an overrepresentation of females in the survey total. Research enumera-
tors limited their household visits to daylight and early evening hours, thereby missing some
males who work outside the home. To control for this, we weighted our sample according to
the demographics in those two areas. Another limitation related to the data collection related
to the start of the rainy season in January. This resulted in some delays in our data collection
which meant that the results were not available to the district health teams before March /
April, after the time when the district budgets were allocated. Based on the results of our end-
line survey, it appears that this delay did not affect the uptake of recommendations that showed
an impact on coverage and compliance.
Conclusions and recommendations for future action
District health staff may not be aware of the actual compliance (drug ingestion) in their area
due to use of different definitions in reporting or metrics used in calculation [10] therefore
they may be surprisedwhen they do not fulfill pre TAS and TAS requirements. During the 4–6
year course of MDA, it is therefore recommended to carry out at least one coverage survey to
assess the presence of a coverage-compliance gap in IUs especially where directly observed
treatment is not enacted. Furthermore in those areas where coverage has known to be problem-
atic or a considerable coverage-compliance gap is known, district health staff may not always
have the tools or information to understand how to improve their MDA. Therefore it is recom-
mended to consider this tool as a substitute coverage survey before reaching the pre-TAS stage
so that results can be interpreted and applied towards the next MDA. Using a tool such as the
one presented here could alert district health staff as to where to re-direct their efforts to ensure
effective drug distribution and that distributed drugs are actually ingested.
District health teams whomust implement additional MDA rounds can benefit from spe-
cialized technical support based on reliable social research findings. It is recommended that
national programs consider on a case-by-case basis which IUs would be helped most by a pro-
cess as describedhere. This would ensure that valuable resources are not invested into MDA
systems that continue to underperformwithout first having a deeper understanding of barriers
to uptake and where programmatic adjustments can be made. Moreover, when additional
MDA rounds are needed, staff report feeling demoralized and uncertain as to how they would
secure additional funds to support furtherMDA rounds. Assistance with advocacy and under-
standing of the TAS requirements should be available to IUs that must continue MDAs beyond
their planning. This is especially recommended in decentralizedhealth systems where the local
government provides some of the funding for MDA activities.
The tool and process used in this implementation research reveal that districts have the
potential to implement their own feasible and affordable improvements to MDA without addi-
tional funds and with minimal technical support. It is recommended to further promote this
tool and the implementation research process so that national programs can assist and guide
IUs that appear to be problematic with their MDA interventions.
Furthermore a tailored approach that aims to reach specific groups in the population is an
effectiveway to improve both drug distribution and uptake. By recognizing that all population
groups will not respond to MDA in the same way, the district programs in this research
reached out more efficiently and effectively to their populations and demonstrated better MDA
outcomes as a result. Simple promotional materials like flowcharts, frequently asked question
sheets (FAQ) and drug packaging inserts aid those individuals at the frontline of drug
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distribution and do not require a significant financial commitment to develop and reproduce.
These tools can be tailored to the context and those factors that have been shown to influence
both coverage and compliance.
The cost of improving a program’s drug coverage rates reduces the necessity for future
MDA rounds. It is recommended to evaluate the cost effectiveness of this technique so that it
can be balanced against the cost of additional MDA rounds where improvement in reported
coverage rates does not occur.
Finally a research tool based on people’s experienceswith the MDA program provided reli-
able and valid results that could be interpreted into feasible and applicable recommendations
for the LF program. It is recommended that the use of this micronarrative methodologybe
more widely explored in other areas where health behavior is studied.
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